Sagimet Biosciences Inc. - Seri (SGMT) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.31

Estimate

-$0.27

Surprise

-13.1%

Score today

6.0/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Sagimet Biosciences Inc. - Seri (SGMT) reported a wider loss than forecast — adjusted EPS of -$0.31 against the -$0.27 estimate (a 13.1% shortfall).

• Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Corporate Updates — fiscal.ai, 2026-11-12
• Sagimet Expects Topline Data From US Phase 3 AURORA Acne Trial In 2H 2027 — benzinga, 2026-11-12
• Sagimet Says Cash Runway Into Mid-2029; Pro Forma Cash & Investments About $356M — benzinga, 2026-11-12

TrendMatrix currently rates SGMT Sell at 6.0/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -13.1% surprise compares with a +6.6% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$10.93

Price target

$24.28

Stop

$10.16

Upside to target

+122.1%

Reward-to-risk

8.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$775.0M

P/E (fwd)

-8.5

52-week range

$4.50–$11.45

Off 52-week high

4.5%

RSI (14)

61

Volume vs avg

1.25×

Score today

6.0/10